Myelodysplastic Syndrome-Pipeline Review, H2 2016
1
Description: Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections. Request a sample of this report @ http://www.orbisresearch.com/contacts/requestsample/148564 .
Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 11, 62, 55, 3, 13 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 6, 7, 2, 1 and 2 molecules, respectively.Myelodysplastic Syndrome. Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse the complete report @ http://www.orbisresearch.com/reports/index/myelodysplasticsyndrome-pipeline-review-h2-2016 .
Companies Mentioned: 4SC AG AbbVie Inc Acceleron Pharma Inc Actinium Pharmaceuticals Inc 2
Aeglea BioTherapeutics Inc Agios Pharmaceuticals Inc Aileron Therapeutics Inc Altor BioScience Corp Amgen Inc Apogenix GmbH Ariad Pharmaceuticals Inc Arno Therapeutics Inc Arog Pharmaceuticals Inc Array BioPharma Inc If you have any enquiry before buying a copy of this report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/148564 .
List of Figures Number of Products under Development for Myelodysplastic Syndrome, H2 2016 27 Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H2 2016 28 Number of Products under Development by Companies, H2 2016 29 Number of Products under Investigation by Universities/Institutes, H2 2016 36 Contact
[email protected] for more information. About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. Contact Us: Hector Costello Senior Manager – Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A. Phone No.: +1 (214) 884-6817; +912064101019 Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research Follow us on Twitter: https://twitter.com/orbisresearch Like us on Facebook: https://www.facebook.com/pages/Orbis-Research/820969017982115 3